바이오모아 (BioMoa) — ADC · Antibody

9268프로그램 35FDA 승인

0오늘 방문

572누적 방문

8122갱신 대기 S–CData Tier S/A/B차세대 1068HER2 breast 5456Antibody 2744CGT →Psoriasis →NSCLC 35FDA 승인

피드 Data Tier 차세대

최근 활동

RSS →

CGTBiologicstaleFrontiergate Biopharm（Hainan） C…Phase 1

Claudin18.2-targeted CAR-DCs (Claudin18.2-targeted CAR-DCs)

Colorectal Neoplasia · Colorectal Neoplasia

#ColorectalNeoplasia#CGT#Phase1#세포유전치료#CAR-T+2

임상시험 2상태 RECRUITING

ADCBiologicstaleAbbViePhase 1

ABBV-838 (ABBV-838)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1

임상시험 2상태 DISCONTINUED

AntibodystaleRochePhase 2

atezolizumab (Tecentriq, YL201 and atezolizumab)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#항체#면역항체+2

임상시험 2상태 RECRUITING

ADCBiologicstaleGenentech, Inc.Phase 2

Pinatuzumab Vedotin (Pinatuzumab Vedotin)

Follicular Lymphoma; Diffuse Large B-Cell Lymphoma · Follicular Lymphoma

#FollicularLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 6.24%임상시험 2상태 ACTIVE

ADCBiologicstaleSeagen Inc.Phase 1

ASG-5ME (ASG-5ME)

Gastric Neoplasms; Pancreatic Neoplasms · Gastric Neoplasms

#GastricNeoplasms#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

임상시험 2상태 ACTIVE

AntibodystaleBeiGenePhase 3

Ociperlimab (Ociperlimab)

Advanced Hepatocellular Carcinoma · FRα

#FR#Antibody#Phase3#항체#면역항체+3

효능 ORR 100%임상시험 2상태 DISCONTINUED

AntibodystaleHoffmann-La RocheApproved

Daclizumab (Daclizumab)

Type 1 Diabetes Mellitus · Myelodysplastic Syndromes

#MyelodysplasticSyndromes#Antibody#Approved#항체#면역항체+3

효능 ORR 20%임상시험 2상태 ACTIVE

AntibodystaleBristol Myers SquibbPhase 2

HF10 plus Ipilimumab (HF10 plus Ipilimumab)

Malignant Melanoma · Malignant Melanoma

#MalignantMelanoma#Antibody#Phase2#항체#면역항체+2

임상시험 2상태 ACTIVE

ADCBiologicBayerSN-38, which is predominant…Phase 1

BAY 3547922 (BAY 3547922)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3

임상시험 2상태 RECRUITING

ADCBiologicstaleAstraZenecaPhase 1

[111In]-FPI-2107 ([111In]-FPI-2107)

Advanced Solid Tumor; Metastatic Colorectal Carcinoma · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

임상시험 2상태 RECRUITING

CGTBiologicstaleBeijing BiotechPhase 2

Dual-target CAR-NK cells (Dual-target CAR-NK cells)

Malignant Glioma; High-Grade Gliomas · Malignant Glioma

#MalignantGlioma#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 2상태 RECRUITING

CGTBiologicstaleM.D. Anderson Cancer CenterPhase 2

TGFBR2 KO CAR27/IL-15 NK cells (TGFBR2 KO CAR27/IL-15 NK cells)

Gastric Cancer, Metastatic · Lymphoid

#Lymphoid#CGT#Phase2#세포유전치료#CAR-T+4

임상시험 2상태 RECRUITING

AntibodystaleGenmabPhase 2

Acasunlimab (Acasunlimab)

Non Small Cell Lung Cancer Metastatic · Non Small Cell Lung Cancer Metastatic

#NonSmallCellLungCancerMetastatic#Antibody#Phase2#항체#면역항체+2

임상시험 2상태 RECRUITING

CGTAAVBiologicstaleNational Human Genome Research …Phase 2

AAV9-GLB1 (AAV9-GLB1)

Lysosomal Diseases; Gangliosidosis · Lysosomal Diseases

#LysosomalDiseases#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 2상태 RECRUITING

AntibodyBiologicstaleShanghai Kechow Pharma, Inc.Phase 2

Tunlametinib+PD-1 mAb (Tunlametinib+PD-1 mAb)

Gastric Adenocarcinoma · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+3

임상시험 2상태 RECRUITING

CGTBiologicstaleGuangdong Xiangxue Precision Me…Phase 2

NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy） (NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）)

Soft Tissue Sarcoma · Bone Sarcoma

#BoneSarcoma#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 2상태 ACTIVE

CGTBiologicstaleTScan Therapeutics, Inc.Phase 2

E7 TCR (E7 TCR)

Papillomavirus Infections; Oropharyngeal Neoplasms · Cervical Intraepithelial Neoplasia

#CervicalIntraepithelialNeoplasia#CGT#Phase2#세포유전치료#CAR-T+4

효능 ORR 5%임상시험 2상태 DISCONTINUED

CGTBiologicstaleHenan Academy of Innovations in…Phase 1

Autologous NK cells (Autologous NK cells)

Malignant Solid Brain Tumors; Glioblastoma (GBM) · Malignant Solid Brain Tumors

#MalignantSolidBrainTumors#CGT#Phase1#세포유전치료#CAR-T+3

효능 ORR 0.667%임상시험 2상태 ACTIVE

CGTBiologicstaleMiltenyi Biomedicine GmbHPhase 1

T-cell Receptor-engineered T-cells (T-cell Receptor-engineered T-cells)

Prostate Carcinoma; Prostate Small Cell Neuroendocrine Carcinoma · Metastatic Malignant Solid Neoplasm

#MetastaticMalignantSolidNeoplasm#CGT#Phase1#세포유전치료#CAR-T+4

효능 ORR 32%임상시험 2상태 RECRUITING

CGTBiologicstaleImmune Design, a subsidiary of …Phase 1

Dendritic Cell-targeting Lentiviral Vector ID-LV305 (Dendritic Cell-targeting Lentiviral Vector ID-LV305)

HLA-A*0201 Positive Cells Present; NY-ESO-1 Positive Tumor Cells Present · HLA-A*0201 Positive Cells Present

#HLA-A0201PositiveCellsPresent#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 2상태 ACTIVE

AntibodystaleMerckPhase 3

MK-3475 (Pembrolizumab, Pembrolizumab (MK-3475))

Merkel Cell Carcinoma · Biliary Tract Neoplasms

#BiliaryTractNeoplasms#Antibody#Phase3#항체#면역항체+3

효능 ORR 49.1%임상시험 2상태 RECRUITING

CGTBiologicstaleAnhui Kecheng intelligent healt…Phase 2

METR-NK cell（metabolic remodeling nature killer cells） (METR-NK cell（metabolic remodeling nature killer cells）)

Ovarian Cancer · Ovary Cancer

#OvaryCancer#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 2상태 RECRUITING

CGTBiologicstaleBiohaven Pharmaceuticals, Inc.Phase 2

CIML NK Cell Infusion (CIML NK Cell Infusion)

Squamous Cell Carcinoma of the Head and Neck; Recurrent Head and Neck Squamous Cell Carcinoma · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase2#세포유전치료#CAR-T+4

임상시험 2상태 ACTIVE

CGTBiologicstaleCARsgen Therapeutics Co., Ltd.Preclinical

CAR-CLD18 T Cells (CAR-CLD18 T Cells)

Advanced Gastric Adenocarcinoma; Pancreatic Adenocarcinoma · Advanced Gastric Adenocarcinoma

#AdvancedGastricAdenocarcinoma#CGT#Preclinical#세포유전치료#CAR-T+3

임상시험 2상태 ACTIVE

CGTBiologicstaleSeigo NishidaPhase 1

Liver NK cell inoculation (Liver NK cell inoculation)

Liver Cirrhosis; Hepatocellular Carcinoma · Liver Cirrhosis

#LiverCirrhosis#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 2상태 ACTIVE

57 / 167 페이지

← 이전 다음 →

전체 9,268개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 0 / 572

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

Claudin18.2-targeted CAR-DCs (Claudin18.2-targeted CAR-DCs)

ABBV-838 (ABBV-838)

atezolizumab (Tecentriq, YL201 and atezolizumab)

Pinatuzumab Vedotin (Pinatuzumab Vedotin)

ASG-5ME (ASG-5ME)

Ociperlimab (Ociperlimab)

Daclizumab (Daclizumab)

HF10 plus Ipilimumab (HF10 plus Ipilimumab)

BAY 3547922 (BAY 3547922)

[111In]-FPI-2107 ([111In]-FPI-2107)

Dual-target CAR-NK cells (Dual-target CAR-NK cells)

TGFBR2 KO CAR27/IL-15 NK cells (TGFBR2 KO CAR27/IL-15 NK cells)

Acasunlimab (Acasunlimab)

AAV9-GLB1 (AAV9-GLB1)

Tunlametinib+PD-1 mAb (Tunlametinib+PD-1 mAb)

NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy） (NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）)

E7 TCR (E7 TCR)

Autologous NK cells (Autologous NK cells)

T-cell Receptor-engineered T-cells (T-cell Receptor-engineered T-cells)

Dendritic Cell-targeting Lentiviral Vector ID-LV305 (Dendritic Cell-targeting Lentiviral Vector ID-LV305)

MK-3475 (Pembrolizumab, Pembrolizumab (MK-3475))

METR-NK cell（metabolic remodeling nature killer cells） (METR-NK cell（metabolic remodeling nature killer cells）)

CIML NK Cell Infusion (CIML NK Cell Infusion)

CAR-CLD18 T Cells (CAR-CLD18 T Cells)

Liver NK cell inoculation (Liver NK cell inoculation)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

Claudin18.2-targeted CAR-DCs (Claudin18.2-targeted CAR-DCs)

ABBV-838 (ABBV-838)

atezolizumab (Tecentriq, YL201 and atezolizumab)

Pinatuzumab Vedotin (Pinatuzumab Vedotin)

ASG-5ME (ASG-5ME)

Ociperlimab (Ociperlimab)

Daclizumab (Daclizumab)

HF10 plus Ipilimumab (HF10 plus Ipilimumab)

BAY 3547922 (BAY 3547922)

[111In]-FPI-2107 ([111In]-FPI-2107)

Dual-target CAR-NK cells (Dual-target CAR-NK cells)

TGFBR2 KO CAR27/IL-15 NK cells (TGFBR2 KO CAR27/IL-15 NK cells)

Acasunlimab (Acasunlimab)

AAV9-GLB1 (AAV9-GLB1)

Tunlametinib+PD-1 mAb (Tunlametinib+PD-1 mAb)

NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy） (NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）)

E7 TCR (E7 TCR)

Autologous NK cells (Autologous NK cells)

T-cell Receptor-engineered T-cells (T-cell Receptor-engineered T-cells)

Dendritic Cell-targeting Lentiviral Vector ID-LV305 (Dendritic Cell-targeting Lentiviral Vector ID-LV305)

MK-3475 (Pembrolizumab, Pembrolizumab (MK-3475))

METR-NK cell（metabolic remodeling nature killer cells） (METR-NK cell（metabolic remodeling nature killer cells）)

CIML NK Cell Infusion (CIML NK Cell Infusion)

CAR-CLD18 T Cells (CAR-CLD18 T Cells)

Liver NK cell inoculation (Liver NK cell inoculation)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

Claudin18.2-targeted CAR-DCs (Claudin18.2-targeted CAR-DCs)

ABBV-838 (ABBV-838)

atezolizumab (Tecentriq, YL201 and atezolizumab)

Pinatuzumab Vedotin (Pinatuzumab Vedotin)

ASG-5ME (ASG-5ME)

Ociperlimab (Ociperlimab)

Daclizumab (Daclizumab)

HF10 plus Ipilimumab (HF10 plus Ipilimumab)

BAY 3547922 (BAY 3547922)

[111In]-FPI-2107 ([111In]-FPI-2107)

Dual-target CAR-NK cells (Dual-target CAR-NK cells)

TGFBR2 KO CAR27/IL-15 NK cells (TGFBR2 KO CAR27/IL-15 NK cells)

Acasunlimab (Acasunlimab)

AAV9-GLB1 (AAV9-GLB1)

Tunlametinib+PD-1 mAb (Tunlametinib+PD-1 mAb)

NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy） (NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）)